This is a competitive renewal of the Western New England Pediatric AIDS Clinical Trials Unit (WNEPACTU) and is submitted in conjunction with the Pediatric AIDS Clinical Trials Unit Group (PACTG) Coordinating and Operations Center (CORC) application. The WNEPACTU was established in 1992 and consists of a main unit at the University of Massachusetts Medical School, Worcester, MA and two subunits located at Baystate Medical Center in Springfield, MA and the University of CT Health Science Center in Farmington, CT. The WNEPACTU has been a national and international leader in the study of the pathogenesis of vertical HIV-1 infection. Investigators from WNEPACTU have held PACTG leadership positions and have played a major role in the development and accomplishment of the scientific agenda. The primary objectives of the WNEPACTU are: 1. To improve our understanding of the pathogenesis of HIV-1 infection in infants, children, and adolescents and to improve treatment strategies for all stages of pediatric HIV-1 infection (Primary Therapy RAC). 2. To improve our understanding of the pathogenesis of vertical HIV-1 transmission and to improve strategies to prevent vertical HIV-1 globally (Perinatal RAC). 3. To improve our understanding of the immunopathogenesis of pediatric HIV -1 infection, to evaluate the capacity for and potential role of immunomodulatory agents in immune reconstitution following antiretroviral therapy, and to evaluate vaccine approaches to prevent vertical and pediatric HIV-1 infection (Immunology/IBT/RAC). 4. To define potential adverse outcomes of antiretroviral therapy, to improve strategies to prevent or treat complications of HIV-1 infection or antiretroviral therapy, to better understand determinants of medication adherence in pediatric populations, and to improve the overall quality of life for HIV-1 infected children and their families (Complications of HIV RAC). 5. To improve our understanding of the viral and immunopathogenesis of adolescent HIV-1 infection and, in turn, improve strategies to prevent or treat adolescent HIV-1 infection (Adolescent Committee). Our history of scientific contributions, performance, and leadership coupled with our unique expertise to help answer the scientific agenda makes the WNEPACTU an ideal site for continued membership in the Pediatric AIDS Clinical Trials Group.

National Institute of Health (NIH)
National Institute of Allergy and Infectious Diseases (NIAID)
Research Project--Cooperative Agreements (U01)
Project #
Application #
Study Section
Special Emphasis Panel (ZAI1-PSS-A (J1))
Program Officer
Germuga, Donna E
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Massachusetts Medical School Worcester
Schools of Medicine
United States
Zip Code
McManus, Margaret; Mick, Eric; Hudson, Richard et al. (2016) Early Combination Antiretroviral Therapy Limits Exposure to HIV-1 Replication and Cell-Associated HIV-1 DNA Levels in Infants. PLoS One 11:e0154391
Aweeka, F T; Hu, C; Huang, L et al. (2015) Alteration in cytochrome P450 3A4 activity as measured by a urine cortisol assay in HIV-1-infected pregnant women and relationship to antiretroviral pharmacokinetics. HIV Med 16:176-83
Aldrovandi, Grace M; Chu, Clara; Shearer, William T et al. (2009) Antiretroviral exposure and lymphocyte mtDNA content among uninfected infants of HIV-1-infected women. Pediatrics 124:e1189-97
Cohn, Susan E; Umbleja, Triin; Mrus, Joseph et al. (2008) Prior illicit drug use and missed prenatal vitamins predict nonadherence to antiretroviral therapy in pregnancy: adherence analysis A5084. AIDS Patient Care STDS 22:29-40
Read, J S; Best, B M; Stek, A M et al. (2008) Pharmacokinetics of new 625 mg nelfinavir formulation during pregnancy and postpartum. HIV Med 9:875-82
Mirochnick, Mark; Best, Brookie M; Stek, Alice M et al. (2008) Lopinavir exposure with an increased dose during pregnancy. J Acquir Immune Defic Syndr 49:485-91
McComsey, Grace A; Kang, Minhee; Ross, Allison C et al. (2008) Increased mtDNA levels without change in mitochondrial enzymes in peripheral blood mononuclear cells of infants born to HIV-infected mothers on antiretroviral therapy. HIV Clin Trials 9:126-36
Hitti, Jane; Andersen, Janet; McComsey, Grace et al. (2007) Protease inhibitor-based antiretroviral therapy and glucose tolerance in pregnancy: AIDS Clinical Trials Group A5084. Am J Obstet Gynecol 196:331.e1-7
Tremoulet, Adriana H; Capparelli, Edmund V; Patel, Parul et al. (2007) Population pharmacokinetics of lamivudine in human immunodeficiency virus-exposed and -infected infants. Antimicrob Agents Chemother 51:4297-302
Stek, Alice M; Mirochnick, Mark; Capparelli, Edmund et al. (2006) Reduced lopinavir exposure during pregnancy. AIDS 20:1931-9

Showing the most recent 10 out of 33 publications